New Antiplatelet Game Plan: Optimal Outcomes for ACS Patients Post-PCI
14 Oct 2024 • In a comprehensive analysis involving over 103,000 patients, researchers evaluated various antiplatelet strategies for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI).
- In patients with ACS who undergo coronary stenting, dual‐antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 inhibitor (prasugrel, ticagrelor, or clopidogrel) for 12 months is the recommended reasonable approach to limit the risk of stent thrombosis and recurrent myocardial infarction
- A new study compared the traditional 12-month dual-antiplatelet therapy (DAPT) of aspirin and clopidogrel to four alternative regimens.
- Aspirin and ticagrelor for 3 months, followed by aspirin and clopidogrel for the remaining duration, can be considered the optimal strategy for treating post–percutaneous coronary intervention patients with acute coronary syndrome because of a significantly reduced risk of major adverse cardiovascular events without increasing the risk of bleeding.
This evolving strategy may reshape treatment protocols for post-PCI ACS patients, enhancing both safety and outcomes.
Source: JAHA | Read full story